Inhibition of Anti-Apoptotic Bcl-2 Proteins in Preclinical and Clinical Studies: Current Overview in Cancer
The dynamic interplay between pro-death and pro-survival Bcl-2 family proteins is responsible for a cell’s fate. Due to the recognized relevance of this family in cancer progression and response to therapy, different efforts have made in recent years in order to develop small molecules able to targe...
Main Authors: | Simona D’Aguanno, Donatella Del Bufalo |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-05-01
|
Series: | Cells |
Subjects: | |
Online Access: | https://www.mdpi.com/2073-4409/9/5/1287 |
Similar Items
-
Anti‐apoptotic protein BCL‐XL as a therapeutic vulnerability in gastric cancer
by: Yumin Wei, et al.
Published: (2023-06-01) -
Identification of Aloperine as an anti-apoptotic Bcl2 protein inhibitor in glioma cells
by: Zhijie Xu, et al.
Published: (2019-09-01) -
Emerging biomarkers and potential therapeutics of the BCL-2 protein family: the apoptotic and anti-apoptotic context
by: Md. Saddam, et al.
Published: (2024-01-01) -
The ZIKA Virus Delays Cell Death Through the Anti-Apoptotic Bcl-2 Family Proteins
by: Jonathan Turpin, et al.
Published: (2019-10-01) -
Bcl-xL: A Focus on Melanoma Pathobiology
by: Anna Maria Lucianò, et al.
Published: (2021-03-01)